Brian Lipworth1. 1. Asthma and Allergy Research Group, Ninewells Hospital and Medical School, Dundee, Scotland. B.j.lipworth@dundee.ac.uk
Abstract
OBJECTIVE: To review the available methods of evaluating the small airways disease in asthma and the therapeutic strategies to achieve better control using emerging extrafine particle inhaler technologies. DATA SOURCES: The PubMed, MEDLINE (Ebsco), Scirus, Scopus, and Google Scholar databases were all scanned with Cross-search using the following keywords: asthma, small airways, hydrofluoroalkane 134a, extrafine particle, inhaled corticosteroid, long-acting β-agonist, spirometry, impulse oscillometry, nitrogen washout, exhaled nitric oxide, airway hyperresponsiveness, and adrenal suppression. STUDY SELECTION: Key clinical studies considered to being relevant to the topic under review were evaluated. RESULTS: There is an unmet need in current asthma guidelines for those individuals who exhibit the small airways asthma phenotype with a preserved forced expiratory volume in 1 second but abnormal forced midexpiratory flow and peripheral airway resistance, which tends to be associated with poorer control. Extrafine hydrofluoroalkane solution formulations of inhaled corticosteroid either alone or in combination with long-acting β-agonist may improve small airways outcomes and associated control. CONCLUSION: From a pragmatic perspective, it makes sense to try to deliver asthma treatment to more of the lung to improve clinical outcomes, especially in patients who exhibit the small airways asthma phenotype.
OBJECTIVE: To review the available methods of evaluating the small airways disease in asthma and the therapeutic strategies to achieve better control using emerging extrafine particle inhaler technologies. DATA SOURCES: The PubMed, MEDLINE (Ebsco), Scirus, Scopus, and Google Scholar databases were all scanned with Cross-search using the following keywords: asthma, small airways, hydrofluoroalkane 134a, extrafine particle, inhaled corticosteroid, long-acting β-agonist, spirometry, impulse oscillometry, nitrogen washout, exhaled nitric oxide, airway hyperresponsiveness, and adrenal suppression. STUDY SELECTION: Key clinical studies considered to being relevant to the topic under review were evaluated. RESULTS: There is an unmet need in current asthma guidelines for those individuals who exhibit the small airways asthma phenotype with a preserved forced expiratory volume in 1 second but abnormal forced midexpiratory flow and peripheral airway resistance, which tends to be associated with poorer control. Extrafine hydrofluoroalkane solution formulations of inhaled corticosteroid either alone or in combination with long-acting β-agonist may improve small airways outcomes and associated control. CONCLUSION: From a pragmatic perspective, it makes sense to try to deliver asthma treatment to more of the lung to improve clinical outcomes, especially in patients who exhibit the small airways asthma phenotype.
Authors: Marcello Cottini; Carlo Lombardi; Giovanni Passalacqua; Diego Bagnasco; Alvise Berti; Pasquale Comberiati; Gianluca Imeri; Massimo Landi; Enrico Heffler Journal: Front Med (Lausanne) Date: 2022-05-23
Authors: Richard J Martin; David Price; Nicolas Roche; Elliot Israel; Willem M C van Aalderen; Jonathan Grigg; Dirkje S Postma; Theresa W Guilbert; Elizabeth V Hillyer; Anne Burden; Julie von Ziegenweidt; Gene Colice Journal: NPJ Prim Care Respir Med Date: 2014-10-09 Impact factor: 2.871
Authors: Dirkje S Postma; Richard Dekhuijzen; Thys van der Molen; Richard J Martin; Wim van Aalderen; Nicolas Roche; Theresa W Guilbert; Elliot Israel; Daniela van Eickels; Javaria Mona Khalid; Ron M C Herings; Jetty A Overbeek; Cristiana Miglio; Victoria Thomas; Catherine Hutton; Elizabeth V Hillyer; David B Price Journal: Allergy Asthma Immunol Res Date: 2017-03 Impact factor: 5.764
Authors: Céline El Baou; Rachael L Di Santostefano; Rafael Alfonso-Cristancho; Elizabeth A Suarez; David Stempel; Mark L Everard; Neil Barnes Journal: BMC Pulm Med Date: 2017-02-07 Impact factor: 3.317